查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197721

神經康復設備市場-增長、趨勢、COVID-19 影響和預測 (2023-2028)

Neurorehabilitation Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

神經康復設備市場預計在預測期內（2022 年至 2027 年）的複合年增長率為 13.7%。

COVID-19 對神經康復設備市場的增長產生了重大影響。 例如，根據 2021 年 10 月發表的題為“COVID-19 大流行期間的遠程神經康復：對中低收入國家 (LMIC) 實踐的啟示”的研究，遠程康復可以幫助對抗大流行情況。但是，它有被認為是一項重要的創新和減少全球殘疾的有效戰略。 我們還報告說，大流行情景提供了一個機會來優化和擴大與醫學相關的技術進步，以解決 LMIC 中日益增加的神經系統疾病負擔。 因此，COVID-19 對市場增長產生了顯著影響。

神經康復設備有助於改善功能、減輕症狀並改善外傷、神經系統疾病和其他疾病患者的健康狀況。 2020 年 2 月發表的一項題為“年輕人缺血性中風：全球視角”的研究發現，全世界每年大約發生 1100 萬例缺血性中風，其中一半以上是中低規模的。我們知道它發生在收入國家。 缺血性中風是導致長期殘疾的主要原因，對患者和護理人員的生活質量有重大影響。 缺血性中風日益增加的負擔正在推動市場的增長，因為神經康復設備用於大約 40% 的缺血性中風病例並且可以改善神經功能。

此外，隨著老年人更容易患急性腦梗塞、阿爾茨海默病和帕金森病等各種神經系統疾病，老齡化速度的加快也推動了市場增長。 例如，根據聯合國公佈的《2020年世界人口老齡化亮點》，2020年世界老年人口（65歲及以上）將達到7.27億，預計到2050年底將達到15億。我在這。 因此，預計世界上不斷增加的老年人口將產生對更多神經康復設備的需求，這將對所研究市場的增長產生重大影響。

此外，國際監管機構對神經康復設備的批准也有助於預測期內的市場增長。 例如，2021 年 4 月，美國食品和藥物管理局推出了 IpsiHand 上肢康復系統（IpsiHand System），這是一種腦機接口（BCI）設備，用於幫助中風患者康復上肢或手、腕部殘疾，或武器。授予授權。

因此，神經系統疾病患病率上升、老年人口增加以及神經康復設備技術進步是市場增長的主要驅動力。 然而，神經康復設備的高成本可能會阻礙預測期內的市場增長。

神經康復設備的市場趨勢

在神經康復設備市場，神經機器人設備領域有望佔據主要市場份額

神經機器人設備細分市場預計神經康復設備市場將出現顯著增長。 神經系統疾病負擔的增加、機器人技術的進步、與神經科學的融合以及新產品的發布預計在預測期內將顯示出類似的趨勢。

神經機器人設備結合了神經科學和康復，是一種治療神經系統疾病的新方法，可根據您想要恢復的特定功能提供不同的治療方法。 用於神經康復的機器人設備可大致分為兩類，例如末端執行器設備和外骨骼，具體取決於人與機器人之間的物理交互類型。

為了解機器人方法在神經康復中的有效性而進行的研究也將有助於這些設備的採用，從而推動這一領域的發展。 例如，在 2020 年 5 月發表的題為“小兒神經康復中的機器人技術”的研究中，在意大利一家兒科醫院進行的人為因素試點研究中，在使用機器人進行神經康復治療後，患者報告說生活質量和滿意度有所提高。 接受機器人治療的患者父母也報告了比接受常規治療的患者略高的期望和滿意度。 還表明，機器人神經康復方法顯著提高了患者和家長的期望。 因此，神經機器人設備在各種研究中的高效能可能會增加對這些設備的採用並刺激該領域的發展。

此外，新成立的機器人輔助神經康復中心提高了神經機器人設備的可及性，預計這將有助於該細分市場的增長。 例如，2021 年 12 月，領先的醫療機構之一撒克拉世界醫院 (Sakra World Hospital) 在印度卡納塔克邦推出了世界一流的機器人輔助神經康復中心。

因此，神經系統疾病患病率上升、與神經機器人設備相關的好處、機器人輔助神經康復中心的建立以及技術進步是神經機器人設備領域的主要驅動因素。.

北美將佔據很大的市場份額，預計在預測期內也會如此

由於中風、阿爾茨海默病、帕金森病發病率上升、老年人口增加以及該地區神經康復設備技術的進步，預計北美將在全球神經康復設備市場佔據重要市場份額。

根據美國疾病控制和預防中心 2022 年 5 月的更新，每年大約有 795,000 人經歷新發或複發中風。 流行病學數據顯示，美國大約 87% 的中風是缺血性中風。 缺血性中風的增加將導致該地區神經康復設備的採用增加，從而推動北美同一市場的增長。

主要參與者旨在提高對神經康復的認識和採用的舉措越來越多，預計將在預測期內進一步推動美國這一市場的增長。 例如，2021 年 9 月，Evolution Devices 啟動了 EvoWalk 平台試點項目，為神經性部分步態麻痺患者提供步態康復服務。 該公司的方法將遠程物理治療 (PT) 與其 EvoWalk 智能刺激設備相結合，以幫助患者避免跌倒並恢復本能運動。

此外，2021年12月，國際非營利社區組織老鷹兄弟會（F.O.E）內布拉斯加州分部將代表當地內布拉斯加州住院康復機構提供EksoNR設備。你說你買了兩個。 因此，越來越多地採用這些神經康復設備也促進了市場增長。

此外，對神經康復設備好處的認識不斷提高以及成熟的醫療基礎設施的存在也顯著推動了該地區的市場增長。

神經康復器械市場競爭者分析

神經康復設備市場是整合的，由幾家主要參與者組成。 從市場份額的角度來看，一些主要參與者主導著市場。 目前主導市場的公司有 Hocoma AG、Bionik Labs、St. Jude Medical Inc.（Abbott Laboratories）、Electron Ltd、MagVenture A/S、Helius Medical Technologies、Ekso Bionics、Rehabtronics Inc 和 Rehab-Robotics Company. Limited， ETC。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第1章介紹

  • 研究假設和市場定義
  • 調查範圍

第2章研究方法論

第 3 章執行摘要

第4章市場動態

  • 市場概覽
  • 市場驅動因素
    • 神經系統疾病患病率上升
    • 神經康復設備技術進步
  • 市場製約因素
    • 神經康復設備的高成本
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按產品類型
    • 神經機器人設備
    • 可穿戴設備
    • 無創刺激器
    • 腦機接口
  • 最終用戶
    • 醫院/診所
    • 失智症護理中心
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章競爭格局

  • 公司簡介
    • Hocoma AG
    • Bionik Labs
    • Abbott Laboratories（St. Jude Medical Inc）
    • Ectron Ltd
    • MagVenture A/S
    • Helius Medical Technologies
    • Ekso Bionics
    • Rehabtronics Inc
    • Rehab-Robotics Company Limited
    • Eodyne Systems S.L.
    • Neofect
    • Neuro Rehab VR
    • Reha Technology AG
    • ReWalk Robotics Ltd.

第7章 市場機會與今後動向

簡介目錄
Product Code: 67835

The neurorehabilitation devices market is expected to register a CAGR of 13.7% during the forecast period (2022-2027).

COVID-19 has had a significant impact on the growth of the neurorehabilitation market. For instance, according to the study titled "Tele-Neurorehabilitation During the COVID-19 Pandemic: Implications for Practice in Low- and Middle-Income Countries (LMICs)" published in October 2021, telerehabilitation had been perceived as a key innovation and an effective strategy to combat the pandemic situation and lower the worldwide handicap load. It also reported that the pandemic scenario presented an opportunity to optimize and scale-up health-related technology advancements to tackle the rising burden of neurological impairment in LMICs. Thus, COVID-19 had a pronounced impact on the growth of the market.

Neurorehabilitation devices help improve function, reduce symptoms, and improve the well-being of people with diseases such as trauma or nervous system disorders. As per the research study published in February 2020, titled "Ischemic stroke in young adults: a global perspective," about 11 million cases of ischemic stroke occur every year across the world, of which more than half occur in low- and middle-income countries. Ischemic stroke is a major cause of long-term disability and has a profound effect on the quality of life of patients and caregivers. Since neurorehabilitation devices can be used in nearly 40% of cases of ischemic stroke to improve neurological functions, thereby growing burden of ischemic stroke augments the market growth.

In addition, the rise in the aging population is also driving the growth of this market, as the elderly population is vulnerable to various neurological disabilities such as acute ischemic stroke, Alzheimer's disease, and Parkinson's disease, among others. For instance, according to the World Population Aging Highlight of 2020 published by the United Nations, the global geriatric population (people aged 65 years or more) was 727 million in 2020, and it is expected to reach 1.5 billion by the end of 2050. Thus, the growing global geriatric population is expected to create a need for more neurorehabilitation devices, thus significantly impacting the growth of the market studied.

In addition, approvals for neurorehabilitation devices by international regulatory agencies also contribute to the market growth over the forecast period. For instance, in April 2021, the United States Food and Drug Administration granted marketing approval for the IpsiHand Upper Extremity Rehabilitation System (IpsiHand System), a brain-computer-interface (BCI) device that assists in rehabilitation for stroke patients with upper extremity or hand, wrist, and arm disability.

Therefore, the rising prevalence of neurological disorders, the growing geriatric population, and technological advancements in neurorehabilitation devices are the key driving factors for the market's growth. However, the high cost of neurorehabilitation devices may hinder market growth over the forecast period.

Neurorehabilitation Devices Market Trends

Neuro-Robotic Devices Segment is Expected to Hold a Major Market Share in the Neurorehabilitation Devices Market

The neuro-robotic devices segment projects significant growth in the neurorehabilitation devices market. It is anticipated to show a similar trend over the forecast period owing to the increasing burden of neurological diseases, technological advancements in robotics, and its combination with neuroscience, coupled with the launch of newer products.

Neuro-robotic devices combined with neuroscience and rehabilitation are the new methods for treating neurological disorders, which provide different ways of treatment depending on the specific function to be restored. Robotic devices for neurorehabilitation can be divided into two main categories based on the different types of physical human-robot interactions, such as end-effector devices and exoskeletons.

The research studies performed to understand the effectiveness of the robotic approach in neurorehabilitation also contribute to the adoption of devices and thus drive the growth of the segment. For instance, the study titled "Robotic Technology in Pediatric Neurorehabilitation" in a Pilot Study of Human Factors in an Italian Pediatric Hospital, published in May 2020, stated that patients reported improved quality of life and satisfaction after using robotic neurorehabilitation treatment. It also reported that the parents of patients who received robotic therapy had slightly greater expectations and satisfaction than those receiving conventional therapy. The study also showed that the robotic neurorehabilitation approach resulted in a considerable improvement in patient and parent expectations. Thus, the high effectiveness of neurorobotic devices in different studies may lead to increased adoption of these devices, thereby driving the growth of the segment.

Additionally, the establishment of new robotic-assisted neurorehabilitation centers improved the accessibility to neuro-robotic devices and is thus expected to contribute to segment growth. For instance, in December 2021, Sakra World Hospital, one of the leading healthcare organizations, launched a world-class robotic-assisted neuro-rehabilitation center in Karnataka, India.

Thus, the rising prevalence of neurological disorders, benefits associated with neuro-robotic devices, the establishment of robotic-assisted neurorehabilitation centers, and technological advancements are the key driving factors in the neuro-robotic devices segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global neurorehabilitation devices market due to growing incidences of stroke, Alzheimer's, and Parkinson's disease, growing geriatric population, and technological advancements in neurorehabilitation devices in this region.

According to the Centers for Disease Control and Prevention's May 2022 update, about 795,000 people experience a new or recurrent type of stroke every year. As per the epidemiology data, approximately 87% of strokes in the United States are ischemic. The rise in ischemic stroke will lead to increased neurorehabilitation device adoption in this region, thereby driving the growth of this market in North America.

Rising initiatives from the key players to increase awareness and growing adoption of neurorehabilitation are further expected to drive the growth of this market in the United States during the forecast period. For instance, in September 2021, Evolution Devices launched its EvoWalk Platform pilot program for the rehabilitation of walking for those living with neurologically based partial walking paralysis. The company's approach combines remote physical therapy (PT) with its EvoWalk smart stimulation device to help patients avoid falls and get instinctual movement back.

In addition, in December 2021, the Nebraska Chapter of the Fraternal Order of Eagles ("F.O.E."), an international non-profit community organization, purchased two EksoNR devices on behalf of local Nebraska inpatient rehabilitation facilities. Therefore, the rising adoption of these neurorehabilitation devices also drives the market growth.

Furthermore, increasing awareness regarding the benefits of neurorehabilitation devices and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Neurorehabilitation Devices Market Competitor Analysis

The neurorehabilitation devices market is consolidated and consists of a few major players. In terms of market share, a few major players dominate the market. Some companies currently dominating the market are Hocoma AG, Bionik Labs, St. Jude Medical Inc. (Abbott Laboratories), Electron Ltd, MagVenture A/S, Helius Medical Technologies, Ekso Bionics, Rehabtronics Inc., and Rehab-Robotics Company Limited.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Neurological Disorders
    • 4.2.2 Technological Advancements in Neurorehabilitation Devices
  • 4.3 Market Restraints
    • 4.3.1 High Cost of the Neurorehabilitation Devices
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Neuro-Robotic Devices
    • 5.1.2 Wearable Devices
    • 5.1.3 Non-Invasive Stimulators
    • 5.1.4 Brain-Computer Interface
  • 5.2 By End-User
    • 5.2.1 Hospitals/Clinics
    • 5.2.2 Cognitive Care Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Hocoma AG
    • 6.1.2 Bionik Labs
    • 6.1.3 Abbott Laboratories (St. Jude Medical Inc)
    • 6.1.4 Ectron Ltd
    • 6.1.5 MagVenture A/S
    • 6.1.6 Helius Medical Technologies
    • 6.1.7 Ekso Bionics
    • 6.1.8 Rehabtronics Inc
    • 6.1.9 Rehab-Robotics Company Limited
    • 6.1.10 Eodyne Systems S.L.
    • 6.1.11 Neofect
    • 6.1.12 Neuro Rehab VR
    • 6.1.13 Reha Technology AG
    • 6.1.14 ReWalk Robotics Ltd.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS